Equities Research

Filing Date Description Downloads
Jul 03, 2023 AGM and recent financing
Jun 01, 2023 Full Year 2022 Results
May 12, 2023 First transaction on KIN001
Apr 11, 2023 Receptive environment for KIN001
Jan 03, 2023 Implications of recent news flow
Nov 09, 2022 Strategic Update
Sep 30, 2022 KINETIC study results
Sep 07, 2022 Making p38 MAP kinase inhibition viable
Filing Date Description Downloads
May 15, 2023 Kinarus secures CHF1.5m financing
Dec 07, 2022 Antiviral activity against Omicron BA.2 and BA.5
Nov 24, 2022 USPTO allows method-of-use KIN001 patent
Oct 03, 2022 KINETIC study discontinued
Sep 05, 2022 H122 results reflect continued progress
Aug 31, 2022 Phase II COVID-19 outpatient study underway
Aug 24, 2022 A unique combination targeting unmet needs